Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

8.5K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
8.5K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

2.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
2.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and molecular characterization of thrombocytosis in transient abnormal myelopoiesis.

Leukemia·2026
Same author

Polycomb repressive complex 2 insufficiency underlies myeloid leukemia in Down syndrome.

Blood·2026
Same author

IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs.

Blood advances·2026
Same author

Concurrent Somatic Mutations of the SETBP1 and KRAS Genes in Pediatric AML: A Case Report.

Pediatric blood & cancer·2026
Same author

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph<sup>+</sup> Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Pediatric blood & cancer·2026
Same author

A Pilot Study to Develop an Ultrasensitive Thio-NAD Cycling ELISA for Neisseria gonorrhoeae Detection.

Biological & pharmaceutical bulletin·2026

Related Experiment Video

Updated: Apr 25, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.0K

Recurrent CDC25C mutations drive malignant transformation in FPD/AML.

Akihide Yoshimi1, Takashi Toya1, Masahito Kawazu2

  • 11] Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan [2].

Nature Communications
|August 28, 2014
PubMed
Summary

Mutations in CDC25C are common in familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML). These CDC25C mutations disrupt cell cycle checkpoints, driving malignant transformation and serving as an early biomarker for FPD/AML progression.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

945

Related Experiment Videos

Last Updated: Apr 25, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.0K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

945

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Familial platelet disorder (FPD) with predisposition to acute myeloid leukemia (AML) involves platelet defects and a high risk of hematological malignancies.
  • The molecular basis of FPD/AML is largely unknown, with germline RUNX1 mutations being the primary identified cause.

Purpose of the Study:

  • To investigate the molecular pathogenesis of FPD/AML.
  • To identify novel genetic mutations contributing to FPD/AML development and progression.

Main Methods:

  • Genetic sequencing of FPD/AML patients.
  • Analysis of cell cycle regulation and DNA damage response pathways.
  • Hierarchical clonal architecture prediction.

Main Results:

  • CDC25C mutations were identified in 53% of FPD/AML patients.
  • Mutated CDC25C impairs the G2/M checkpoint, promoting cell cycle progression despite DNA damage.
  • CDC25C mutations appear to establish a pre-leukaemic clone, with subsequent mutations (e.g., in GATA2) driving leukaemia progression.
  • CDC25C mutations were found to be a potential early clinical biomarker for FPD/AML progression.

Conclusions:

  • CDC25C is a novel gene implicated in the pathogenesis of FPD/AML.
  • CDC25C mutations play a critical role in the malignant transformation of FPD/AML.
  • CDC25C serves as a valuable biomarker for predicting early-stage FPD/AML progression.